HIKMA PHARMACEUTICALS PLC ANNUAL REPORT 2015 Financial Statements Continued Notes to the Company Financial Statements Continued 48.
Investments in subsidiaries Investments in subsidiaries represent the following: Ownership% Ownership% Ordinary shares at Ordinary shares at Companys name Incorporated in 31 December 2015 31 December 2014 Hikma Limited UK 100 100 Hikma Pharma Limited Jersey 100 100 Hikma Acquisitions UK Limited UK 100 100 Al Jazeera Pharmaceutical Industries Ltd KSA 52.5 52.5 Hikma MENA Holdings UAE 100 100 AMKI MENA Holdings Ltd UAE 100 100 Hikma International N. V Netherlands 100 100 Eurohealth International SARL Switzerland 100 100 Hikma Finance Luxembourg SARL Luxembourg 100 100 The investments in subsidiaries are all stated at cost.
The remaining shares are held by other Group companies.
The following table provides the movement of the investments in subsidiaries: 2015 2014 $m $m Beginning balance 2,033 1,678 Additions 355 Reduction of paid up capital 145 Ending balance 1,888 2,033 The 2014 additions relate to a capital increase in Hikma Finance Luxembourg SARL $318 million and a capital contribution to Eurohealth International SARL $37 million.
In 2015, the capital of Hikma Finance Luxembourg SARL was reduced by $108 million.
In addition, the capital contribution of $37 million to Eurohealth International SARL was reversed as the conditions of the contribution were not satisfied.
Part of this capital reduction is related to the transfer of intangibles from sister companies.
